MX385794B - Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. - Google Patents

Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.

Info

Publication number
MX385794B
MX385794B MX2015002994A MX2015002994A MX385794B MX 385794 B MX385794 B MX 385794B MX 2015002994 A MX2015002994 A MX 2015002994A MX 2015002994 A MX2015002994 A MX 2015002994A MX 385794 B MX385794 B MX 385794B
Authority
MX
Mexico
Prior art keywords
trem
tlt
transcript
peptides derived
myeloid cells
Prior art date
Application number
MX2015002994A
Other languages
English (en)
Spanish (es)
Other versions
MX2015002994A (es
Inventor
Amir Boufenzer
Hafid Ait-Oufella
Marc Derive
Sébastien Gibot
Original Assignee
Inst Nat Sante Rech Med
Univ De Lorraine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ De Lorraine filed Critical Inst Nat Sante Rech Med
Publication of MX2015002994A publication Critical patent/MX2015002994A/es
Publication of MX385794B publication Critical patent/MX385794B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015002994A 2012-09-07 2013-09-09 Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos. MX385794B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306079 2012-09-07
PCT/EP2013/068628 WO2014037565A2 (en) 2012-09-07 2013-09-09 Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof

Publications (2)

Publication Number Publication Date
MX2015002994A MX2015002994A (es) 2016-01-14
MX385794B true MX385794B (es) 2025-03-18

Family

ID=46826397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002994A MX385794B (es) 2012-09-07 2013-09-09 Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.

Country Status (24)

Country Link
US (1) US9657081B2 (enExample)
EP (1) EP2892920B1 (enExample)
JP (1) JP6307080B2 (enExample)
KR (1) KR102181384B1 (enExample)
CN (1) CN104837865B (enExample)
AU (1) AU2013311606B2 (enExample)
CA (1) CA2884121C (enExample)
CY (1) CY1123014T1 (enExample)
DK (1) DK2892920T3 (enExample)
ES (1) ES2797625T3 (enExample)
HR (1) HRP20200875T8 (enExample)
HU (1) HUE051557T2 (enExample)
IL (1) IL237615B (enExample)
LT (1) LT2892920T (enExample)
MX (1) MX385794B (enExample)
NZ (1) NZ705899A (enExample)
PL (1) PL2892920T3 (enExample)
PT (1) PT2892920T (enExample)
RS (1) RS60421B1 (enExample)
RU (1) RU2672341C2 (enExample)
SI (1) SI2892920T1 (enExample)
SM (1) SMT202000309T1 (enExample)
WO (1) WO2014037565A2 (enExample)
ZA (1) ZA201501779B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
JP7284557B2 (ja) * 2015-06-12 2023-05-31 マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル 医薬組成物
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
WO2021105137A1 (en) 2019-11-25 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
CA3180293A1 (en) * 2020-06-05 2021-12-09 Marc Derive Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection
WO2021263167A2 (en) 2020-06-26 2021-12-30 Amgen Inc. Il-10 muteins and fusion proteins thereof
EP4304626A1 (en) 2021-03-12 2024-01-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Trem-1 inhibitors for the treatment of marfan syndrome
JP2024527514A (ja) 2021-06-25 2024-07-25 アムジエン・インコーポレーテツド Trem-1抗原結合タンパク質での循環器疾患の治療
WO2025196177A1 (en) 2024-03-21 2025-09-25 Institut National de la Santé et de la Recherche Médicale Use of soluble trem-1 as a biomarker for assessing the risk of cardiovascular disease in asymptomatic subjects

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
ATE341638T1 (de) 1993-02-22 2006-10-15 Univ Rockefeller Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
WO1996008563A1 (en) 1994-09-12 1996-03-21 Schering Aktiengesellschaft Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2388061A1 (en) * 2000-08-22 2002-02-28 The Brigham And Women's Hospital, Inc Diagnosis and treatment of cardiovascular conditions
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US7553936B2 (en) * 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
WO2009013319A1 (en) 2007-07-23 2009-01-29 Bioxell Spa Screening, therapy and diagnosis
DE102009018620A1 (de) 2009-04-27 2010-10-28 Carefusion Germany 234 Gmbh Ansteuer- und Auswerteschaltung, Messgerät sowie Verfahren zum Messen der Konzentration eines Gases
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
AU2011237851B2 (en) * 2010-04-08 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from TREM-Like Transcript 1 (TLT-1) and uses thereof

Also Published As

Publication number Publication date
EP2892920A2 (en) 2015-07-15
RU2672341C2 (ru) 2018-11-14
CA2884121C (en) 2021-10-12
IL237615A0 (en) 2015-04-30
ZA201501779B (en) 2016-10-26
PT2892920T (pt) 2020-06-16
CA2884121A1 (en) 2014-03-13
IL237615B (en) 2018-12-31
SI2892920T1 (sl) 2020-08-31
JP6307080B2 (ja) 2018-04-04
HRP20200875T8 (hr) 2021-04-30
KR20150110460A (ko) 2015-10-02
HRP20200875T1 (hr) 2020-09-04
RU2015112625A (ru) 2016-10-27
RS60421B1 (sr) 2020-07-31
AU2013311606A1 (en) 2015-04-09
AU2013311606B2 (en) 2017-10-05
WO2014037565A9 (en) 2015-06-11
HUE051557T2 (hu) 2021-03-01
EP2892920B1 (en) 2020-03-04
CN104837865B (zh) 2019-09-24
NZ705899A (en) 2018-08-31
ES2797625T3 (es) 2020-12-03
KR102181384B1 (ko) 2020-11-20
PL2892920T3 (pl) 2020-08-24
LT2892920T (lt) 2020-07-10
MX2015002994A (es) 2016-01-14
CN104837865A (zh) 2015-08-12
WO2014037565A2 (en) 2014-03-13
DK2892920T3 (da) 2020-06-08
US20150232531A1 (en) 2015-08-20
WO2014037565A3 (en) 2014-05-15
SMT202000309T1 (it) 2020-07-08
HK1212360A1 (en) 2016-06-10
US9657081B2 (en) 2017-05-23
CY1123014T1 (el) 2021-10-29
JP2015533791A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
MX385794B (es) Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
AR070962A1 (es) Uso de defensinas contra la tuberculosis
MX339277B (es) Agente inductor de inmunidad.
MX337417B (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores.
UA118167C2 (uk) Пептид та його застосування
EP3936141A3 (en) Anti-senescence compounds and uses thereof
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
PE20091214A1 (es) Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion
WO2010144231A3 (en) Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
JP2014519526A5 (enExample)
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
RU2009129531A (ru) Вакцины на основе пептида foxp3
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
AR119056A2 (es) Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
HRP20170794T1 (hr) Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a
AR083766A1 (es) Peptido inmunogenico
ES2605171T3 (es) Composiciones ansiolíticas que comprenden péptidos derivados de la Caseína ALFAs1
AR098615A1 (es) Péptido para el tratamiento de hipoglicemia severa
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo